Bladder cancer awareness month – May 2024

May 1, 2024

Bladder Cancer Awareness day, NHS consultant urologists

Today, 1st May, is the first day of bladder cancer awareness month. We are working with organisations across the private and public sectors to help raise awareness of this cancer, its symptoms and the novel, non-invasive test and services we offer that could transform the healthcare journey for thousands of patients.

Bladder cancer in the UK  

  • In the UK, around 20,500 people are diagnosed with bladder cancer in every year[i], leading to around 5,500 deaths.[ii]
  • Early diagnosis of the disease is crucial – more than 80 per cent of people diagnosed at the earliest stage survive at least five years compared to less than 10 per cent diagnosed at the latest stage[iii].


Testing for bladder cancer

Blood in the urine (haematuria) is one of the most common signs of bladder cancer. Patients with this indication are primarily investigated by cystoscopy, which is an uncomfortable and expensive hospital procedure that involves a camera being inserted into the urethra.

However, a novel, non-invasive test offered by Informed Genomics has the potential to spare thousands of patients the discomfort of receiving a cystoscopy, whilst freeing up clinicians’ time and resources to deal with the most urgent patients.

Developed by our sister company Nonacus, in partnership with clinical researchers at the Bladder Cancer Research Centre, University of Birmingham, the GALEAS™ Bladder test requires a simple urine sample from the patient and delivers results equivalent to that of cystoscopy for all stages of bladder cancer. The barcoded urine sample is sent to Informed Genomics UK laboratory where our team of HCPC registered clinical scientists perform the test, analyse the data and generate a report for clinicians.

Find out more about our Bladder Cancer Testing services. 


National newspaper The Telegraph recently ran an article on bladder cancer, citing the GALEAS™ Bladder test as “A recent breakthrough in diagnostics could make it easier to detect patients early.”

Read about GALEAS Bladder in The Telegraph


Collaborations in bladder cancer testing

It has been six months since we announced a partnership with Bupa – the first health insurer in the UK to cover GALEAS™ bladder test for customers.  Dr Tim Woodman, Medical Director for Cancer Services at Bupa said: “We’re pleased to be partnering with Informed Genomics to be the first UK health insurer to cover the GALEAS Bladder test for our customers. It provides a more efficient solution to diagnosing bladder cancer, where getting that diagnosis a few days or weeks earlier could make a crucial difference.”

There is also recognition across the NHS that the Informed Genomics bladder cancer testing service has the potential to transform bladder cancer care. Here’s what some of the UK’s leading Consultant Urologists have to say… 




“The Galeas Bladder test offers a genuine non-invasive option in diagnostic pathways and to potentially ‘de-intensify’ follow-up regimes.”

Sachin Agrawal, Ashford and St. Peter’s Hospitals NHS Foundation Trust

“The recent incredible advances in precision oncology gives both primary and secondary care clinician’s easier, quicker, and more bespoke access to earlier cancer diagnoses. The GALEAS Bladder has the potential to be a game-changer in the world of bladder cancer diagnosis and surveillance, and I am extremely happy to be able to offer this test to NHS patients and help shape the future of bladder cancer care.”

Richard Tippett, The Cancer Screening Trust and NHS 

“The GALEAS Bladder test, developed by the University of Birmingham and Nonacus Ltd, is a significant innovation in the field of bladder cancer diagnostics. This test utilises a non-invasive, urine-based approach to detect bladder cancer by identifying changes in the cell’ DNA which is usually seen in cancer cells. It offers a convenient alternative to the traditional and more invasive cystoscopy method, which involves inserting a camera into the bladder.

“The GALEAS Bladder test represents a major advancement in bladder cancer diagnosis, offering a highly sensitive, non-invasive, and patient-friendly alternative to traditional diagnostic methods. Its ability to accurately detect and monitor bladder cancer through simple urine samples could significantly improve patient outcomes and optimise healthcare resources.”

Ashwin Sridhar, University College London Hospitals NHS Foundation

[i] Catto JWF et al. Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU Int. 2023 Jun;131(6):734-744.



Share this post on Social Media: